An evaluation of sotalol, a β-blocking agent, in patients with angina pectoris

146 patients (103 men, 43 women) with angina pectoris confirmed by history and electrocardiographic changes, mean age 55 years. Key exclusions: hyperthyroidism, bronchial asthma, myocardial infarction within the preceding 3 months, uncompensated heart failure, previous cardiac surgery, second and third degree heart block, resting pulse rate below 60/min, or severe hepatic or renal impairment.

Sotalol oral, titrated to an optimum dose (ranging from 120 to 480 mg/day, with 92.5% between 240 and 480 mg/day) for a 6-week treatment period.

Matching placebo for a 6-week treatment period.

Number of anginal attacks per weekpatient reported